Adial Pharmaceuticals, Inc.
ADIL
$0.33
$0.013.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.36% | -9.75% | 9.33% | -20.37% | 2.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.23% | -17.69% | 22.89% | 8.80% | 62.86% |
| Operating Income | 20.23% | 17.69% | -22.89% | -8.80% | -62.86% |
| Income Before Tax | 18.16% | 20.33% | 65.59% | -8.74% | -62.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.16% | 20.33% | 65.59% | -8.74% | -62.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.16% | 20.33% | 65.59% | -7.84% | -58.25% |
| EBIT | 20.23% | 17.69% | -22.89% | -8.80% | -62.86% |
| EBITDA | 20.23% | 17.69% | -22.89% | -8.80% | -62.86% |
| EPS Basic | 78.46% | 68.62% | 84.46% | 60.75% | 68.04% |
| Normalized Basic EPS | 78.44% | 68.64% | 84.46% | -33.37% | 67.16% |
| EPS Diluted | 78.46% | 68.62% | 84.46% | 60.75% | 68.04% |
| Normalized Diluted EPS | 78.44% | 68.64% | 84.46% | -33.37% | 67.16% |
| Average Basic Shares Outstanding | 279.93% | 153.96% | 121.40% | 174.79% | 395.18% |
| Average Diluted Shares Outstanding | 279.93% | 153.96% | 121.40% | 174.79% | 395.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |